# Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT02588612** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 10 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** letetresgene autoleucel (GSK3377794)
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT02588612
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-01
- **Primary completion:** 2020-08-10
- **Final completion:** 2020-08-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588612, "Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02588612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*